Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital PIC

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

Fineline Cube Aug 26, 2026
Company Deals

Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones

Fineline Cube Aug 26, 2026
Company Deals PIC

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug

MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC

Fineline Cube Mar 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...

Company

Sandoz Expands Antibiotics Production with New Austrian Factory

Fineline Cube Mar 25, 2024

Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics...

Company Drug

Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments

Fineline Cube Mar 25, 2024

Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...

Company Drug

EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision

Fineline Cube Mar 25, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company

Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market

Fineline Cube Mar 25, 2024

Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of...

Company

Roche Invests EUR 90 Million in New Gene Therapy Center in Germany

Fineline Cube Mar 25, 2024

Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in...

Company Drug

Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges

Fineline Cube Mar 25, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...

Company Drug

FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia

Fineline Cube Mar 25, 2024

FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it...

Policy / Regulatory

China’s Commerce Minister Meets with Global Pharma Leaders to Discuss Innovation Cooperation

Fineline Cube Mar 25, 2024

China’s Minister of Commerce, Wang Wentao, convened a high-level meeting with top executives from the...

Company Drug

Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU

Fineline Cube Mar 25, 2024

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary...

Company Deals

OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development

Fineline Cube Mar 25, 2024

OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...

Company Drug

Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs

Fineline Cube Mar 25, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Medical Device

Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System

Fineline Cube Mar 25, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...

Company Deals Digital

Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics

Fineline Cube Mar 25, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into...

Company Deals

Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments

Fineline Cube Mar 25, 2024

Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China,...

Company Deals Drug

Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China

Fineline Cube Mar 25, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...

Company Deals

AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China

Fineline Cube Mar 25, 2024

AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous...

Company Deals

Sino Biological Partners with Rapid Novor to Market mAb Sequencing Services Across Asia

Fineline Cube Mar 22, 2024

Sino Biological Inc. (SHE: 301047), a leading supplier of reagents based in China, has announced...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase III Trial for Atopic Dermatitis Treatment

Fineline Cube Mar 22, 2024

Lynk Pharmaceuticals Co., Ltd, based in China, has announced the dosing of the first patient...

Company Drug

HutchMed Launches Phase II/III Study for Sovleplenib in Autoimmune Hemolytic Anemia

Fineline Cube Mar 22, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of the Phase II/III...

Posts pagination

1 … 431 432 433 … 712

Recent updates

  • NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
  • FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
  • FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
  • MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
  • WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.